Talus Bio Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 27

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 47

Talus Bio General Information

Description

Developer of a data-enabled drug development platform designed to offer small-molecule therapy in oncology. The company's platform combines cell processing with high-sensitivity quantitative proteomics and machine learning analytics, focusing on drug discovery through gene regulation, enabling the healthcare sector to advance drug development for gene control.

Contact Information

Website
www.talus.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 550 17th Avenue
  • Suite 550
  • Seattle, WA 98122
  • United States
+1 (206)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 550 17th Avenue
  • Suite 550
  • Seattle, WA 98122
  • United States
+1 (206)

Talus Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Talus Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Accelerator/Incubator 21-Sep-2026 Completed Pre-Clinical Trials
14. Seed Round 20-Aug-2024 Completed Pre-Clinical Trials
13. Grant 01-Feb-2024 Completed Pre-Clinical Trials
12. Grant 20-Sep-2023 Completed Pre-Clinical Trials
11. Grant 01-Jul-2023 Completed Pre-Clinical Trials
10. Grant 01-Apr-2023 Completed Pre-Clinical Trials
9. Seed Round 07-Jun-2022 Completed Pre-Clinical Trials
8. Grant 06-Jun-2022 Completed Pre-Clinical Trials
7. Grant 01-Apr-2022 $790K $1.51M Completed Pre-Clinical Trials
6. Accelerator/Incubator 01-Jan-2022 $1.51M Completed Pre-Clinical Trials
To view Talus Bio’s complete valuation and funding history, request access »

Talus Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed Plus
Seed-4
Seed-3
Seed-2 317,661 $0.000100 8% $0.79 $0.79 1x $0.74 0.73%
Seed-1 7,632,793 $0.000100 8% $0.87 $0.87 1x $0.79 18.18%
To view Talus Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Talus Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a data-enabled drug development platform designed to offer small-molecule therapy in oncology. The company'
Drug Discovery
Seattle, WA
27 As of 2026

Watertown, MA
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Talus Bio Competitors (68)

One of Talus Bio’s 68 competitors is Foghorn Therapeutics, a Formerly VC-backed company based in Watertown, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Foghorn Therapeutics Formerly VC-backed Watertown, MA
Vir Biotechnology Formerly VC-backed San Francisco, CA
etherna Formerly VC-backed Niel, Belgium
PEP-Therapy Venture Capital-Backed Evry Cedex, France
Histogen Formerly VC-backed San Ramon, CA
You’re viewing 5 of 68 competitors. Get the full list »

Talus Bio Patents

Talus Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260226097-A1 Extraction of nuclear and chromatin-bound proteins using volatile salts Pending 03-Feb-2023
WO-2024163959-A2 Extraction of nuclear and chromatin-bound proteins using volatile salts Inactive 03-Feb-2023
WO-2024163959-A3 Extraction of nuclear and chromatin-bound proteins using volatile salts Inactive 03-Feb-2023
EP-4658665-A2 Lectin-assisted isolation of mammalian cell nuclei Pending 03-Feb-2023
US-20260242771-A1 Lectin-assisted isolation of mammalian cell nuclei Pending 03-Feb-2023 C12N15/1013
To view Talus Bio’s complete patent history, request access »

Talus Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Talus Bio Investors (47)

Investor Name Investor Type Holding Investor Since Participating Rounds
Plug and Play Accelerator/Incubator
Funders Club Angel Group Minority
Gaingels Venture Capital Minority
Two Bear Capital Venture Capital Minority
WRF Capital Corporate Venture Capital Minority
You’re viewing 5 of 47 investors. Get the full list »

Talus Bio FAQs

  • When was Talus Bio founded?

    Talus Bio was founded in 2020.

  • Where is Talus Bio headquartered?

    Talus Bio is headquartered in Seattle, WA.

  • What is the size of Talus Bio?

    Talus Bio has 27 total employees.

  • What industry is Talus Bio in?

    Talus Bio’s primary industry is Drug Discovery.

  • Is Talus Bio a private or public company?

    Talus Bio is a Private company.

  • What is Talus Bio’s current revenue?

    The current revenue for Talus Bio is .

  • How much funding has Talus Bio raised over time?

    Talus Bio has raised $19.6M.

  • Who are Talus Bio’s investors?

    Plug and Play, Funders Club, Gaingels, Two Bear Capital, and WRF Capital are 5 of 47 investors who have invested in Talus Bio.

  • Who are Talus Bio’s competitors?

    Foghorn Therapeutics, Vir Biotechnology, etherna, PEP-Therapy, and Histogen are some of the 68 competitors of Talus Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process